These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 36040480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF, Yang YF, Liu BC, Li WM, Xu N, Liu XL, Jiang Q, Dang HB, Liang LX, Zhang Y, Song YP.
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug 14; 43(8):636-643. PubMed ID: 36709147
    [Abstract] [Full Text] [Related]

  • 3. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct 14; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

  • 4. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH, Winton EF, Heffner LT, Chen Z, Langston AA, Hill B, Arellano M, El-Rassi F, Kim A, Jillella A, Kota VK, Bodó I, Khoury HJ.
    Cancer; 2017 Jul 01; 123(13):2482-2488. PubMed ID: 28241101
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J.
    Lancet Haematol; 2015 Mar 01; 2(3):e118-28. PubMed ID: 26687797
    [Abstract] [Full Text] [Related]

  • 10. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L, Wang H, Zhu X, Liu W, Zhou S, Geng Z, Xiao Y, Zou P, You Y, Li Q, Zhu X.
    Stem Cells Dev; 2019 Nov 15; 28(22):1480-1485. PubMed ID: 31530245
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
    Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.
    Clin Cancer Res; 2019 Nov 15; 25(22):6606-6613. PubMed ID: 31292142
    [Abstract] [Full Text] [Related]

  • 12. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
    Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, Ansah HJ, Escoffre-Barbe M, Turhan A, Rousselot P, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG.
    Haematologica; 2024 Sep 01; 109(9):2893-2907. PubMed ID: 38695126
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
    Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D.
    Blood; 2012 Feb 23; 119(8):1838-43. PubMed ID: 22174159
    [Abstract] [Full Text] [Related]

  • 16. [Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia].
    Zhao HF, Zhang Y, Li Z, Zhou J, Zu YL, Yu FK, Gui RR, Wei XD, Song YP.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul 14; 39(7):540-545. PubMed ID: 30122011
    [Abstract] [Full Text] [Related]

  • 17. Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
    Etienne G, Faberes C, Bauduer F, Adiko D, Lifermann F, Dagada C, Lenoir C, Schmitt A, Klein E, Fort MP, Bijou F, Turcq B, Robbesyn F, Durrieu F, Versmée L, Madene S, Moldovan M, Katsahian S, Charles-Nelson A, Lascaux A, Mahon FX, Dulucq S.
    Cancer Med; 2021 Jun 14; 10(11):3635-3645. PubMed ID: 33988316
    [Abstract] [Full Text] [Related]

  • 18. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J, Rea D, Lipton JH.
    Am J Hematol; 2019 Mar 14; 94(3):346-357. PubMed ID: 30394563
    [Abstract] [Full Text] [Related]

  • 19. A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
    Cantoni N, Sommavilla R, Seitz P, Kulenkampff E, Kahn S, Lambert JF, Schmidt A, Zenhaeusern R, Balabanov S.
    BMC Cancer; 2022 Nov 19; 22(1):1192. PubMed ID: 36402993
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
    Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, Winton EF, Jillella AP, McLemore ML, Khoury HJ.
    Clin Lymphoma Myeloma Leuk; 2017 Dec 19; 17(12):e71-e73. PubMed ID: 29032022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.